HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Draft Guidance Drills Down With Details To Cut Pediatric Acetaminophen Overdose Risk

This article was originally published in The Tan Sheet

Executive Summary

FDA suggests new and repeats previous recommendations to reduce the risk of pediatric overdose with acetaminophen products due either to unsupervised ingestion or therapeutic errors. The guidance includes greater detail on delivery devices and labeling information for pediatric acetaminophen OTCs.

You may also be interested in...



Flow Restrictors Limit Children’s Access To Drugs; Standards Needed

Only 6% of children emptied medicine bottles with flow restrictors in 10 minutes, compared to 82% who emptied bottles with incompletely closed child-resistant caps within two minutes, a CDC study shows. But researchers and stakeholders suggest waiting for industry standards to implement flow restrictors.

Campaign Targets Unsupervised Pediatric Drug Ingestion

The Consumer Healthcare Products Association, the Centers for Disease Control and Prevention and a public-private safe-medication initiative launch the “Up and Away and Out of Sight” campaign to educate caregivers about how to stop curious children from consuming drugs without supervision.

Acetaminophen Panel Recommends Standardizing Solid Dose Strength

A joint advisory panel recommended FDA consider standardizing chewable children's acetaminophen products to one strength.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS139543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel